Astellas Pharma Inc.-Unsp ADRALPMY
13F holders, Q2 2024 (June 30)4holders −2
0new positions
2sold out
$9.86avg. 13F price*
At the end of Q2 2024, 4 institutions reported holding Astellas Pharma Inc.-Unsp ADR (ALPMY) in their 13F filings, down 2 from Q1 2024. 0 opened new positions and 2 sold out. The largest holders were Hantz Financial Services, Inc. ($1.6M), Rhumbline Advisers ($331K) and GAMMA Investing LLC ($33K).
- Company
- Astellas Pharma Inc.-Unsp ADR
- CUSIP
- 04623U102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $1K |
All 13F filers, Q1 2024 → Q2 2024: 30,120 shares bought and 4,730 shares sold, net +25,390 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Hantz Financial Services, Inc. | 0.03% | Add +22.7% | 157,913 | $1.6M |
| Rhumbline Advisers | 0.00% | Reduce -11.4% | 33,588 | $331K |
| GAMMA Investing LLC | 0.00% | Add +37.9% | 3,309 | $33K |
| PNC Financial Services Group, Inc. | 0.00% | Reduce -87.0% | 40 | $394 |
"% of holder's portfolio" is ALPMY's weight in each manager's 13F, not the share of Astellas Pharma Inc.-Unsp ADR the manager owns.